The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1207
April 25, 2005
View Complete Issue         Table of Contents 2019 
Ibandronate (Boniva): A New Oral Bisphosphonate
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ibandronate (Boniva): A New Oral Bisphosphonate
April 25, 2005 (Issue: 1207)
Ibandronate (Boniva - Roche/GSK), a new oral bisphosphonate, was recently approved by the FDA in a once-monthly formulation for prevention and treatment of postmenopausal osteoporosis. The drug was initially approved in 2003 as a daily tablet, but...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ibandronate (Boniva): A New Oral Bisphosphonate
Article code: 1207b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.